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Abstract: Long-term oxygen therapy (LTOT) is the treatment proven to improve survival 
in chronic obstructive pulmonary disease (COPD) patients with chronic respiratory failure. It 
also appears to reduce the number of hospitalizations, increase effort capacity, and improve 
health-related quality of life. Standard LTOT criteria are related to COPD patients who have 
PaO2  60 mmHg, are in a clinical stable situation, and are receiving optimal pharmacological 
treatment. According to LTOT guidelines, oxygen should be prescribed for at least 18 hours 
per day although some authors consider 24 hours would be more beneﬁ  cial. The beneﬁ  ts of 
LTOT depend on correction of hypoxemia. Arterial blood gases should be measured at rest. 
During exercise, an effort test should be done to assure adequate SaO2. During sleep, continuous 
monitoring of SaO2 and PaCO2 should be performed to conﬁ  rm correction of SaO2 overnight. 
An arterial blood gas sample should be taken at awakening to assess PaCO2 in order to prevent 
hypoventilation from the oxygen therapy. Several issues that need to be addressed are the use 
of LTOT in COPD patients with moderate hypoxemia, the efﬁ  cacy of LTOT in patients who 
desaturate during exercise or during sleep, the optimal dosage of oxygen supplementation, 
LTOT compliance, and the LTOT prescription in diseases other than COPD.
Keywords: long-term oxygen therapy, COPD, oxygen supplementation, chronic respiratory 
failure, hypoxemia
Beneﬁ  ts of long-term oxygen therapy
Early reports on respiratory failure in patients with chronic obstructive pulmonary disease 
(COPD) suggested that oxygen therapy decreases pulmonary hypertension and red 
cell mass while simultaneously increasing exercise capacity (O’Donohue 1995) In the 
1980s, two landmark multicentre trials, the Nocturnal Oxygen Therapy Trial (NOTT) 
(NOTT 1980) and the Medical Research Council (MRC) (MRC 1981) study, showed 
that long-term oxygen therapy (LTOT) was the sole treatment that improved survival 
in patients with COPD and chronic respiratory failure (CRF), and that these patients 
received oxygen for at least 18 hours/day (Figure 1). These ﬁ  ndings were reafﬁ  rmed 
in later trials (Dubois et al 1994; Zielinski et al 1998). NOTT (1980) and MRC (1981) 
trials led to the establishment of criteria for oxygen therapy in almost every country in 
the developed world (Table 1) (Sanchez-Agudo et al 1998; ATS 1995; Siafakas et al 
1995; Celli et al 2004; Rabe et al 2007). There is also evidence that LTOT has beneﬁ  ts 
other than survival. These include stabilization of pulmonary arterial hypertension, fewer 
cardiac arrhythmias and electrocardiographic ﬁ  ndings suggestive of myocardial ischemia, 
increased exercise capacity, an improvement in neuropsychiatric function and in health-
related quality of life, and a reduction of exacerbations or hospitalizations (Tirlapur and 
Mir 1982; Davidson et al 1988; Morrison and Stovall 1992; Dean et al 1992; Clini et al 
1996; Wedzicha 2000; Ringbaek et al 2002; Eaton et al 2004). However, these clinical 
beneﬁ  ts depend on treatment compliance, the duration of the treatment, and adequate International Journal of COPD 2008:3(2) 232
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correction of hypoxemia (Gorecka et al 1992; Sliwinski et al 
1994; Pepin et al 1996; Plywaczewski et al 2000; Criner 2000; 
Tárrega et al 2002).
Which patients can improve 
with LTOT?
The NOTT and MRC studies demonstrated that LTOT 
improved survival in COPD with resting partial pressure 
of oxygen in arterial blood (PaO2)  60 mmHg either with 
or without hypercapnia. The trial reported by Gorecka and 
colleagues (1997), however, found LTOT had no effect on 
survival in patients with COPD and moderate hypoxemia 
(56–65 mmHg). Does the lack of beneﬁ  ts on survival in 
some patients mean that not all these patients should be 
offered LTOT? Or should we analyze other beneﬁ  ts of 
LTOT rather than survival? From the results of many 
trials it is reasonable to hypothesize that LTOT may ben-
eﬁ  t COPD patients in different ways, such as in exercise 
capacity (Davidson et al 1988; Morrison and Stovall 1992; 
Dean et al 1992), health-related quality of life (Eaton et al 
2004), exacerbations or hospitalizations (Clini et al 1996; 
Ringbaek et al 2002). Therefore, as the recent National 
Heart, Lung, and Blood Institute (NHLBI) workshop 
Figure 1 Comparison of survival curves of NOTT and MRC studies. The poorest 
prognosis was in the MRC controls who received no oxygen. The best survival was in 
the NOTT patients who received oxygen for >19 hours/day. Copyright © 1980, 1981. 
Modiﬁ  ed with permission from [NOTT] Nocturnal Oxygen Therapy Trial Group. 1980. 
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: 
a clinical trial. Nocturnal Oxygen Therapy Trial Group.  Ann Inter Med, 93:391–8; [MRC] 
Medical Research Council Working Party. 1981. Long term domiciliary oxygen therapy 
in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. 
Report of the Medical Research Council Working Party. Lancet, 1:681–5.
Abbreviations: MRC, Medical Research Council; NIH, National Institutes of Health; 
NOTT, Nocturnal Oxygen Therapy Trial.
proposed, we need to consider these other beneﬁ  ts in 
COPD patients independently from the increase in survival 
(Croxton and Bailey 2006).
How to prescribe LTOT?
Supplemental oxygen should be included in the continuum 
of care along with cessation of smoking, pharmacological 
therapy, vaccination, attention to infectious exacerbations, 
and respiratory rehabilitation. Good coping skills, motiva-
tion, and a supportive family inﬂ  uence compliance with 
supplemental oxygen. Patients need to be able to meet the 
criteria for LTOT (Table 1); they must be clinically stable, 
and should be receiving optimal pharmacological treatment 
prior to commencement. The oxygen ﬂ  ow should be titrated 
during the daytime with the patient awake and at rest. It is 
recommended to set the oxygen ﬂ  ow to achieve transcutaneus 
oxygen saturation (SaO2)  90%.
Are we assessing eligibility 
appropriately for LTOT?
Before prescribing LTOT, arterial blood gas measurements 
should be performed at least twice to conﬁ  rm the patient 
meets the criteria for this treatment. However, in clinical 
practice, LTOT is frequently prescribed in an unstable 
clinical situation or after a single assessment, as reported 
by several authors. Levi-Valensi and colleagues (1986) 
found that 23 of 77 patients under LTOT since hospital 
discharge were no longer eligible at 3 months’ follow up. 
More recently, in a randomized trial, Guyatt and colleagues 
(2005) afﬁ  rmed that reassessment of applicants for LTOT 
identiﬁ  ed an appreciable portion of initially eligible patients 
who were no longer eligible.
Should all COPD patients 
with criteria for LTOT be 
treated 24 hours/day?
Although different guidelines recommend LTOT for at least 
18 hours/day, the combined data from the NOTT (1980) and 
MRC (1981) studies indicate that the longer the oxygen-use, 
the greater the beneﬁ  t. Careful observation of data in Figure 1 
reveals that patients who used oxygen 24 hours/day have higher 
survival than the other groups. Some studies have shown that 
COPD patients have severe desaturation during daily activities 
such as walking, eating, or washing (Soguel Schenkel et al 
1996). The NOTT and MRC studies were developed before 
portable oxygen devices were in common use; liquid oxygen 
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It may therefore be advisable to prescribe LTOT in the form of 
liquid oxygen and advice patients to use this therapy all day, 
especially during exercise. Trials investigating the beneﬁ  ts of 
24-hour rather than 18-hour LTOT are needed.
Does the oxygen ﬂ  ow prescribed 
adequately correct saturacion 
of oxygen?
At rest
According to COPD and LTOT treatment guidelines (Sanchez-
Agudo et al 1998; ATS 1995; Siafakas et al 1995; Celli et al 
2004; Rabe et al 2007) the oxygen ﬂ  ow should be titrated during 
the daytime when the patient is clinically stable and awake, using 
the same oxygen source as that received at home. It is recom-
mended to set the oxygen ﬂ  ow to achieve SaO2  90% using 
a pulse oximeter, taking an arterial blood gas sample to assure 
correct titration. An overnight pulse oximetry should be recorded 
during sleep to evaluate the correction in nocturnal SaO2.
From an international survey about LTOT prescription, 
Wijkstra and colleagues (2001) showed that there were 
marked differences among countries as to how LTOT was 
prescribed. In many European countries patients are tested 
in supine rather than sitting position, the target SaO2 varies 
from 90% to 92%, and not all countries measure arterial 
blood gases or test SaO2 during sleep.
During exercise
There are no speciﬁ  c recommendations about oxygen pre-
scription during exercise. Some guidelines advise using an 
effort test to assess the adequate oxygen ﬂ  ow to correct oxy-
gen desaturation. To establish the appropriate oxygen ﬂ  ow 
it is recommended to test patients under increasing oxygen 
ﬂ  ow until SaO2  90%. The most frequently used effort test 
is the 6-minute walking test (6Wt) , which some authors have 
shown to be a reliable measurement. Comparing SaO2 during 
the 6WT with that of ambulatory pulsioximetry, Morante and 
colleagues (2005) showed that the 6WT is a good reﬂ  ection 
of desaturation during daily activities measured by ambula-
tory pulse oximetry. These authors also demonstrated a good 
correlation between the two measurements when patients are 
breathing oxygen (p   0.01) (Tables 2 and 3).
Wijkstra and colleagues’ (2001) international survey 
showed that most countries assess patients during exercise 
to achieve SaO2  90%. However, ATS guidelines and some 
European countries recommend the resting ﬂ  ow rate should 
be increased by 1 l. min−1 or that the same ﬂ  ow rate as at rest 
should be used without testing the oxygen ﬂ  ow rate needed 
during exercise.
During sleep
There are three ways to adjust the oxygen ﬂ  ow during sleep: 
maintaining the resting ﬂ  ow rate, increasing the resting ﬂ  ow 
rate by 1 or 2 .l. min−1, or setting the ﬂ  ow rate according to 
continuous monitoring of SaO2 to maintain SaO2  90%.
Using the resting ﬂ  ow rate, several studies (Plywaczewski 
et al 2000; Tárrega et al 2002, Nisbet et al 2006) have found 
an inadequate correction in nocturnal SaO2 in a high, and 
variable percentage of patients (13%–48%). Various factors 
Table 1 Indications for LTOT in COPD (Cooper 1993)
UNITED STATES
PaO2   55 mmHg or SaO2   88% (room air)
PaO2 56–59 mmHg or SaO2 89%–90%, with (one or more)
Pulmonary hypertension
Evidence of cor pulmonale or edema due to heart failure
Elevated hematocrit ( 56%)
UNITED KINGDOM
1.   COPD (FEV1   1.5 L, FVC   2.0 L), hypoxemia (PaO2   55 mmHg), 
hypercapnia (PaCO2   45 mmHg), and edema. Stability demon-
strated over 3 weeks
2.   As in 1 but without edema or PaCO2   45 mmHg
  Palliative therapy may be prescribed
EUROPE
1. PaO2   55 mmHg, steady-state COPD
2. PaO2 55–65 mmHg with (one or more)
Pulmonary hypertension
Evidence of cor pulmonale or edema due to heart failure
Elevated hematocrit ( 56%)
Restrictive disease with PaO2   55 mmHg
AUSTRALIA
1.   PaO2   56 mmHg, COPD, Right ventricular hypertrophy, polycythe-
mia, and edema
2.   Desaturation  90% on exercise
3.   Refractory dyspnea associated with cardiac failure
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; PaO2, partial pressure of 
oxygen in arterial blood; SaO2, oxygen saturation.
Table 2 comparison of SaO2 under liquid oxygen between the 6 minute 
walking test (6WT) and the ambulatory pulse oximetry (AP)
 6WT  AP  (p)
SaO2 mean (%)  90 (3)  92 (2)  0.28
CT90 (%)  53 (35)  22 (15)  0.47
CT88 (%)  29 (33)  11 (11)  0.1
CT85 (%)  8 (11)  6 (6)  0.6
Abbreviations: Mean SaO2, mean value of saturation of oxihemoglobin; CT90, 
percentage of time with SaO2  90%; CT88, percentage of time with SaO2  88%; 
CT85, percentage of time with SaO2  85% (Morante et al 2005).International Journal of COPD 2008:3(2) 234
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could explain these differences. Firstly, neither of the two 
ﬁ  rst studies (Plywaczewski et al 2000; Tárrega etal 2002) 
excluded diseases associated to COPD, such as pulmonary 
restrictive disorders, that could produce nocturnal desatu-
ration. Secondly, the presence of obstructive sleep apnea 
syndrome (OSAS) was not ruled out.
To prevent sleep desaturation, some guidelines recom-
mend increasing the resting ﬂ  ow rate oxygen 1 or 2.l. min−1. 
In their international study, Wijkstra and colleagues (2001) 
observed that in Canada and US there was a tendency to 
increase the oxygen ﬂ  ow rate during sleep, whereas in most 
European countries the tendency was either to maintain the 
same ﬂ  ow rate as that used during the day or to test patients 
individually.
Oxygen therapy can generate several potentially detri-
mental effects. The most relevant of these is hypercapnia, 
which is mediated by mechanisms such as hypoventilation, 
ventilation-perfusion redistribution, or the Haldane effect. 
Moreover, sleep itself generates ventilatory alterations that 
include a decrease in baseline metabolism, an increase in 
airway resistance, hypotonia of the respiratory pump, and 
decreased sensitivity of respiratory centers. In healthy 
individuals, these alterations generate only small changes 
in PaO2 or PaCO2 during the night, but in COPD patients 
they may cause severe hypoxemia and hypercapnia. In 
this population, physiopathologic phenomena such as greater 
hypoventilation due to a reduction in tidal volume, greater 
alterations in ventilation-perfusion distribution, associated 
OSAS and reduction of mucociliar clearance may also be 
key to increased hypercapnia and development of sleep 
hypoventilation (SH). O´Donoghue and colleagues (2003) 
and Tárrega and colleagues (2002) observed SH in a high 
percentage of COPD patients, 43% and 59%, respectively, 
and suggested the ﬁ  nding was likely due to the oxygen 
therapy. Increasing the resting ﬂ  ow rate by 1 or 2 l min−1 
may therefore exacerbate hypoventilation. Our group recently 
conducted a study to evaluate changes in gas exchange. We 
increased the nocturnal ﬂ  ow rate by 1 liter and observed 
that this induced SH and respiratory acidosis in a signiﬁ  cant 
number of patients who did not have SH when they received 
the same oxygen titration as during the day (34.2% vs. 23.7% 
of patients) (Figures 2 and 3) (Samolski et al in press). 
This ﬁ  nding further supports the hypothesis that oxygen 
can induce hypoventilation. Plant and colleagues (2000) 
had previously shown that a high oxygen ﬂ  ow rate in acute 
respiratory failure in COPD patients was the most frequent 
cause of hypercapnia and led to the need for noninvasive 
ventilation. Such results reinforce the need to evaluate and 
titrate the nocturnal oxygen ﬂ  ow individually, at least in 
hypercapnic COPD patients.
According to some guidelines, continuous monitoring of 
SaO2 should be performed to set the oxygen ﬂ  ow rate during 
sleep to maintain SaO2  90% overnight. We consider arterial 
blood gases should be measured early in the morning to test 
for hypercapnia and respiratory acidosis. If patients present 
these ﬁ  ndings then our advice is to test for the presence of 
OSAS. Once OSAS is ruled out, the best way to treat these 
patients with SH under oxygen therapy may be to use the 
Venturi mask or noninvasive ventilation. The subgroup 
of COPD patients who develop SH under oxygen therapy 
may be the only COPD candidates for whom domiciliary 
noninvasive ventilation therapy is recommended rather 
than LTOT.
What is the role of oxygen 
conservation systems on COPD 
patients undergoing LTOT?
Oxygen conservation systems could optimize the beneﬁ  t of 
LTOT in some patients. Such devices should only be used in 
patients who need low oxygen ﬂ  ow rates. Their effectiveness 
depends on the valve trigger, the patient’s breathing rate, and 
the presence of nasal breathing.
Some studies have shown that conservation systems 
are effective at rest, during sleep and during exercise 
(Tiep et al 1987, 2002; Bower et al 1988; Braun et al 
1992; Cuvelier et al 1999; Garrod et al 1999; Fuhrman 
et al 2004). Cuvelier and colleagues (1999) showed that 
there were no differences in the ventilatory parameters 
when COPD patients used conventional or conservation 
systems for LTOT. Other studies, however, have shown 
that to maintain an adequate SaO2 in some patients it is 
necessary to increase the oxygen ﬂ  ow rate. Conservative 
systems have different characteristics. Bliss and colleagues 
(2004) compared three different models of these systems 
and found that each model gave a different quantity of 
Table 3 Correlation of the SaO2 values between the 6-minute 
walking test (6WT) and the ambulatory pulse oximetry (AP)
 6WT  AP  r  (p)
SaO2 mean (%)  84 (7)  89 (4)  0.7 ( 0.01)
CT90 (%)  77 (34)  53 (32)  0.6 ( 0.01)
CT88 (%)  56 (42)  35 (30)  0.51 ( 0.01)
CT85 (%)  42 (44)  19 (23)  0.65 ( 0.01)
Abbreviations: Mean SaO2, mean value of saturation of oxihemoglobin; CT90, per-
centage of time with SaO2  90%; CT88, percentage of time with SaO2  88%; CT85, 
percentage of time with SaO2  85% (Morante et al 2005).International Journal of COPD 2008:3(2) 235
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oxygen. These systems should be tested individually at 
rest and during exercise.
Recommendations for future 
research
The NHLBI workshop report (Croxton and Bailey 2006) 
recently reported a very interesting review about the current 
state of knowledge of LTOT and proposed topics for future 
research. The most relevant issues for study, according to 
the said paper, are the use of LTOT in COPD patients with 
moderate hypoxemia, the efﬁ  cacy of LTOT in patients who 
desaturate during exercise and sleep, the optimal dosage of 
oxygen supplementation, and the compliance of LTOT.
Three considerations related to LTOT for COPD patients 
with moderate hypoxemia are yet to be addressed. The ﬁ  rst 
of these is that the duration of treatment may need to be 
longer than 18 hours per day. Second, beneﬁ  ts other than 
survival should be considered, such as health-related qual-
ity of life, exercise capacity, or hospitalizations. Third, it 
is necessary to identify subgroups of COPD patients with 
moderate hypoxemia who can beneﬁ  t from LTOT, such as 
patients with pulmonary hypertension, low body mass index, 






Figure 2 Evolution of PaCO2 :  oxygen  ﬂ  ow titrated at daytime,  : 1 litre increase in oxygen ﬂ  ow.
Note: p   0.05 Samolski et al in press.
Abbreviation: PaCO2, partial pressure of oxygen in arterial blood.









Figure 3 Evolution of pH  : oxygen ﬂ  ow titrated at daytime,  : 1 litre increase in oxygen ﬂ  ow.
Note: p   0.05 Samolski et al in press.International Journal of COPD 2008:3(2) 236
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poor exercise capacity, frequent exacerbations, or co-morbid 
cardiac disease.
There is insufﬁ  cient evidence that LTOT can provide ben-
eﬁ  ts to patients with exercise desaturation. Nevertheless, it seems 
logical that episodic hypoxemia may itself have adverse conse-
quences and increase effort dyspnoea. Very few studies have 
been performed to date regarding the role of oxygen therapy for 
COPD patients with sleep desaturation. We can hypothesize that 
oxygen therapy could increase survival by reducing the risk fac-
tors, especially cardiac events, produced by desaturation during 
sleep, and also increase the quality of sleep. From the NOTT and 
MRC studies it seems obvious that 24 hours/day will be much 
more beneﬁ  cial for COPD patients than 18 hours/day, and that 
an adequately adjustment of oxygen ﬂ  ow at rest, during effort, 
and sleep will provide more beneﬁ  ts.
Finally, it is well known that compliance with LTOT is very 
poor in COPD patients. An important goal in the future there-
fore should be to develop patient education strategies regarding 
the use of LTOT and to improve oxygen therapy devices.
Based on these observations concerning LTOT, the 
NHLBI workshop (Croxton and Bailey 2006) proposed four 
trials to investigate the role of: (1) oxygen supplementation 
during ambulation; (2) continuous oxygen supplementation 
for moderate hypoxemia; (3) nocturnal oxygen treatment for 
desaturation during sleep; and (4) detailed, individualized 
prescriptions for LTOT supplementation. We would like to 
add a further topic, addressed to the prescription of LTOT in 
patients with diseases other than COPD, such as restrictive 
pulmonary diseases or cardiac diseases.
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